ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2370

Endothelial Nitric Oxide Synthase Gene Polymorphism As a Risk Factor of Hypertension in Patients with Rheumatoid Arthritis

Mykola Stanislavchuk1,2, Kateryna Zaichko2 and Ayad Sulaiman2, 1Internal Medicine, VNMU n.a. M. Pirogov, Vinnytsia, Ukraine, 2Rheumatology, Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: hypertension, polymorphism and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) and hypertension (HT) are multifactorial polygenic diseases. The incidence of hypertension in patients with RA is higher than in the general population, ranging from 20 to 60%. The role of genetic polymorphisms in the development of this comorbidity is investigated, but there is little information on the subject. So, potentially promising is the study of the prognostic value of gene promoter polymorphism of endothelial nitric oxide synthase NOS3 T-786C (rs2070744) in patients with RA. Additionally NOS3 plays an important role in the regulation of vascular tone, angiogenesis, osteogenesis, inflammation. The aim of the study was to investigate the prevalence of NOS3 T-786C (rs2070744) gene promoter polymorphism in patients with RA and RA associated with hypertension.

Methods: The study involved 148 patients with RA (100% women) aged 47.0 [42.8; 52.0] years, disease duration 78 [48; 120] months, moderate and high disease activity (DAS28> 3.2). The diagnosis of RA was established by ACR/EULAR (2010) criteria. Polymorphism of NOS3 Т786С gene (rs2070744) was performed by PCR (Real-Time PCR, Bio-Rad iCycler IQ5) using a set of «SNP-express» (NPF “Lyteh”, Russia). All studied polymorphism satisfied Hardy-Weinberg equilibrium (χ2 test, p> 0.05). The study was conducted in accordance with the Declaration of Helsinki of the World Medical Association “Ethical principles of medical research involving human subjects” (2000), the requirements of GCP, the applicable national legislation. Statistical analysis of the results was performed by methods of variation statistics in the application package SPSS22 (© SPSS Inc.).

Results: Among the patients with RA normotensive were 83 (56.1%) and 65 (43.9%) patients were hypertensive. In 44 (29.7%) patients with RA hypertension was registered after the onset of RA. In patients without hypertension (n = 83), the frequency of genotypes was as follows: T/T – 43.3% (36 pts) T/C – 44.6% (37 pts), C/C – 12% (10 pts). In RA patients with hypertension (n = 65), the frequency of genotype C/C was significantly higher – 30.8% (20 pts); χ2 = 8,44, p <0.01), and the frequency of genotype TT was conversely lower – 29.8%, than in RA patients without hypertension. Analysis of the common and recessive inheritance patterns showed that patients with RA, carriers of CC genotype, have 3 times higher risk of developing hypertension (OR = 3,24; 95% CI 1,39-7,55) compared to T/T and T/C genotype carriers. Analysis of the dominant inheritance model showed that patients with RA, presence of T/T genotype was characterized by tendency (χ2 = 3.12; p = 0.08) to decrease the risk of hypertension compared to T/C and C/C genotype (OR = 0.54, 95% CI 0.27-1.07).

Conclusion: The association of T786C NOS3 (rs2070744) gene promoter polymorphism with the development of hypertension in patients with rheumatoid arthritis in the Ukrainian population was established. In RA patients the presence of genotype C/C increased risk of hypertension.


Disclosure: M. Stanislavchuk, None; K. Zaichko, None; A. Sulaiman, None.

To cite this abstract in AMA style:

Stanislavchuk M, Zaichko K, Sulaiman A. Endothelial Nitric Oxide Synthase Gene Polymorphism As a Risk Factor of Hypertension in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/endothelial-nitric-oxide-synthase-gene-polymorphism-as-a-risk-factor-of-hypertension-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endothelial-nitric-oxide-synthase-gene-polymorphism-as-a-risk-factor-of-hypertension-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology